<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336564">
  <stage>Registered</stage>
  <submitdate>18/02/2011</submitdate>
  <approvaldate>22/02/2011</approvaldate>
  <actrnumber>ACTRN12611000204943</actrnumber>
  <trial_identification>
    <studytitle>Intravesical instillation therapy for high-risk non-muscle-invasive transitional cell carcinoma of the bladder: Does the strain of Bacillus Calmette-Guerin (BCG) matter?</studytitle>
    <scientifictitle>Assessment of intravesical instillation therapy with two different strains of Bacillus Calmette-Guerin (BCG) in patients with high-risk non-muscle-invasive transitional cell carcinoma of the bladder in terms of recurrence and survival.</scientifictitle>
    <utrn>nil</utrn>
    <trialacronym>nil</trialacronym>
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non-muscle-invasive transitional cell carcinoma of the bladder</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bladder - transitional cell cancer</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>After completed transurethral resection of a bladder tumor (TURBT), patients diagnosed with high-risk non-muscle-invasive transitional cell carcinoma of the bladder, which qualify for a maintenance BCG therapy, are prospectively included in the trial. Patients are randomized into 2 groups: One group will use the strain BCG-Connaught (dose 1.5-5x10E8 CFU, intravesical), the other group the strain BCG-Tice (dose 5x10E8 CFU, intravesical) for the bladder instillation. Within 2 weeks after the TURBT the BCG instillation therapy is begun. A total of 6 bladder instillations are performed in weekly intervals. For the bladder instillation BCG is injected into the bladder by a single use urethral catheter. Intravesical therapy duration is 2 hours. Regular follow-up controls with cystoscopy and urine cytology are performed every 3 months during the first 3 years and then every 6 months until at least 5 years postoperatively.</interventions>
    <comparator>BCG-Tice strain</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Tumor recurrence by cystoscopy and urine cytology</outcome>
      <timepoint>Every 3 months for the first 3 years after the TURBT, then every 6 months until 5 years.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Tumor progression by cystoscopy and urine cytology</outcome>
      <timepoint>Every 3 months for the first 3 years after the TURBT, then every 6 months until 5 years.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall and disease specific survival by phone call to the patient, general practitioner or the familiy.</outcome>
      <timepoint>at the end of the study</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>High-risk non-muscle-invasive transitional cell carcinoma of the bladder requiring BCG-therapy, complete resection of bladder tumors by TURBT.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Muscle-invasive transitional cell carcinoma of the bladder, incomplete resection of tumor by TURBT.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment />
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>6/08/1986</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>149</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Department of Urology, Inselspital Bern</primarysponsorname>
    <primarysponsoraddress>Anna Seiler-Haus
Inselspital
CH-3010 Bern</primarysponsoraddress>
    <primarysponsorcountry>Switzerland</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Department of Urology, Inselspital Bern</fundingname>
      <fundingaddress>Anna Seiler-Haus
Inselspital
CH-3010 Bern</fundingaddress>
      <fundingcountry>Switzerland</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics committee of the canton of Bern</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Frederic Birkhaeuser</name>
      <address>Department of Urology
Inselspital
Anna Seiler-Haus
CH-3010 Bern</address>
      <phone>+41 31 632 36 41</phone>
      <fax />
      <email>frederic.birkhaeuser@insel.ch</email>
      <country>Switzerland</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Frederic Birkhaeuser</name>
      <address>Department of Urology
Inselspital
Anna Seiler-Haus
CH-3010 Bern</address>
      <phone>+41 31 632 36 41</phone>
      <fax />
      <email>frederic.birkhaeuser@insel.ch</email>
      <country>Switzerland</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Frederic Birkhaeuser</name>
      <address>Department of Urology
Inselspital
Anna Seiler-Haus
CH-3010 Bern</address>
      <phone>+41 31 632 36 41</phone>
      <fax />
      <email>frederic.birkhaeuser@insel.ch</email>
      <country>Switzerland</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>